Liver kinase b1 is required for thromboxane receptor-dependent nuclear factor-kB activation and inflammatory responses

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1297-1305

  He, Jinlong ^a,b   Zhou, Yanhong ^a,b   Xing, Junjie ^b   Wang, Qilong ^b   Zhu, Huaiping ^b   Zhu, Yi ^c,d   Zou, Ming Hui ^b,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Endothelial cell; Inflammation; LKB1; NF kB

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; [[1ALPHA,2ALPHA,3BETA,4ALPHA]] 7 [3 [3 HYDROXY 4 (4 IODOPHENOXY) 1 BUTENYL] 7 OXABICYCLO[2,2,1]HEPT 2 YL] 5 HEPTENOIC ACID; CYCLOOXYGENASE 2; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIVER KINASE B1; PHOSPHOTRANSFERASE; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THROMBOXANE A2 DERIVATIVE; THROMBOXANE A2 RECEPTOR; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

AORTA; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS; VASODILATATION;

COX-2; ENDOTHELIAL CELL; INFLAMMATION; LKB1; NF-ΚB;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MODELS, ANIMAL; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, THROMBOXANE; RHO-ASSOCIATED KINASES; SENSITIVITY AND SPECIFICITY; VASCULAR CELL ADHESION MOLECULE-1; VASCULITIS;

EID: 84879074624     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301296     Document Type: Article

References (38)

1. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-Atherogenic properties of adiponectin. Biochimie. 2012;94:2137-2142.
2. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
3. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680-6684.
4. Hayden MS, Ghosh S. Nf-kappab, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012;26:203-234
5. Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci. 2000;921:92-102.
6. Ashton AW, Ware GM, Kaul DK, Ware JA. Inhibition of tumor necrosis factor alpha-mediated NFkappaB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem. 2003;278:11858-11866.
7. Nakao S, Ogtata Y, Shimizu E, Yamazaki M, Furuyama S, Sugiya H. Tumor necrosis factor alpha (TNF-Alpha)-induced prostaglandin E2 release is mediated by the activation of cyclooxygenase-2 (COX-2) transcription via NFkappaB in human gingival fibroblasts. Mol Cell Biochem. 2002;238:11-18.
8. Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc. 1987;46:133-138.
9. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest. 1996;97:949-956.
10. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem. 1995;270:7011.
11. Walsh M, Foley JF, Kinsella BT. Investigation of the role of the carboxylterminal tails of the alpha and beta isoforms of the human thromboxane A(2) receptor (TP) in mediating receptor:-effector coupling. Biochim Biophys Acta. 2000;1496:164-182.
12. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991;349:617-620.
13. Zhang M, Dong Y, Xu J, Xie Z, Wu Y, Song P, Guzman M, Wu J, Zou MH. Thromboxane receptor activates the AMP-Activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res. 2008; 102:328-337.
14. Ashton AW, Yokota R, John G, Zhao S, Suadicani SO, Spray DC, Ware JA. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J Biol Chem. 1999;274:35562-35570.
15. Gao Y, Tang S, Zhou S, Ware JA. The thromboxane A2 receptor activates mitogen-Activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J Pharmacol Exp Ther. 2001;296:426-433.
16. Ashton AW, Ware JA. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res. 2004;95:372-379.
17. Gao Y, Yokota R, Tang S, Ashton AW, Ware JA. Reversal of angiogenesis in vitro, induction of apoptosis, and inhibition of AKT phosphorylation in endothelial cells by thromboxane A(2). Circ Res. 2000;87:739-745.
18. Song P, Zhang M, Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-Associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem. 2009;284:17120-17128.
19. Ishizuka T, Kawakami M, Hidaka T, Matsuki Y, Takamizawa M, Suzuki K, Kurita A, Nakamura H. Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol. 1998;112:464-470.
20. Mindrescu C, Le J, Wisniewski HG, Vilcek J. Up-regulation of cyclooxygenase-2 expression by TSG-6 protein in macrophage cell line. Biochem Biophys Res Commun. 2005;330:737-745.
21. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 2006;38:1654-1661.
22. Coleman RA, Humphrey PP, Kennedy I, Levy GP, Lumley P. Comparison of the actions of U-46619, a prostaglandin H2-Analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations. Br J Pharmacol. 1981;73:773-778.
23. Boyd AW, Wawryk SO, Burns GF, Fecondo JV. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci USA. 1988;85:3095-3099.
24. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990;60:577-584.
25. Bereta M, Bereta J, Georgoff I, Coffman FD, Cohen S, Cohen MC. Methylxanthines and calcium-mobilizing agents inhibit the expression of cytokine-inducible nitric oxide synthase and vascular cell adhesion molecule-1 in murine microvascular endothelial cells. Exp Cell Res. 1994;212:230-242.
26. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor, I kappa B-Alpha. Proc Natl Acad Sci USA. 1993;90:2532-2536.
27. Mellits KH, Hay RT, Goodbourn S. Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B. Nucleic Acids Res. 1993;21:5059-5066.
28. Alkalay I, Yaron A, Hatzubai A, Jung S, Avraham A, Gerlitz O, Pashut-Lavon I, Ben-Neriah Y. In vivo stimulation of I kappa B phosphorylation is not sufficient to activate NF-kappa B. Mol Cell Biol. 1995;15:1294-1301.
29. Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2011;31:125-132.
30. Xie Z, Dong Y, Zhang M, Cui MZ, Cohen RA, Riek U, Neumann D, Schlattner U, Zou MH. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-Activated protein kinase in cultured endothelial cells. J Biol Chem. 2006;281:6366-6375.
31. Xie Z, Dong Y, Scholz R, Neumann D, Zou MH. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metforminenhanced activation of the AMP-Activated protein kinase in endothelial cells. Circulation. 2008;117:952-962.
32. Kent KC, Collins LJ, Schwerin FT, Raychowdhury MK, Ware JA. Identification of functional PGH2/TxA2 receptors on human endothelial cells. Circ Res. 1993;72:958-965.
33. Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M, Mäkelä TP. The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta. 2007;1775:63-75.
34. Bess E, Fisslthaler B, Fromel T, Fleming I. Nitric oxide-induced activation of the amp-Activated protein kinase alpha2 subunit attenuates ikappab kinase activity and inflammatory responses in endothelial cells. PLoS One. 2011;6:-e20848
35. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010;106:1117-1128.
36. Morita M, Yano S, Yamaguchi T, Sugimoto T. Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. J Diabetes Complicat. 2013;27:11-15.
37. Usui T, Okada M, Mizuno W, Oda M, Ide N, Morita T, Hara Y, Yamawaki H. HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats. Am J Physiol Heart Circ Physiol. 2012;302:H1894-H1904.
38. Tang WH, Stitham J, Gleim S, et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest. 2011;121:4462-4476.